| AHNAK2 Promotes the Progression of Differentiated Thyroid Cancer through PI3K/AKT Signaling Pathway. | AHNAK2 Promotes the Progression of Differentiated Thyroid Cancer through PI3K/AKT Signaling Pathway.
Xu M, Wen J, Xu Q, Li H, Lin B, Bhandari A, Qu J. | 02/7/2024 |
| Downregulation of AHNAK2 inhibits cell cycle of lung adenocarcinoma cells by interacting with RUVBL1. | Downregulation of AHNAK2 inhibits cell cycle of lung adenocarcinoma cells by interacting with RUVBL1.
Li X, Li H, Shao MM, Miao J, Fu Y, Hu B., Free PMC Article | 08/4/2023 |
| AHNAK2 promotes thyroid carcinoma progression by activating the NF-kappaB pathway. | AHNAK2 promotes thyroid carcinoma progression by activating the NF-κB pathway.
Ye R, Liu D, Guan H, AiErken N, Fang Z, Shi Y, Zhang Y, Wang S. | 12/4/2021 |
| Down-Regulation of AHNAK2 Inhibits Cell Proliferation, Migration and Invasion Through Inactivating the MAPK Pathway in Lung Adenocarcinoma. | Down-Regulation of AHNAK2 Inhibits Cell Proliferation, Migration and Invasion Through Inactivating the MAPK Pathway in Lung Adenocarcinoma.
Wang DW, Zheng HZ, Cha N, Zhang XJ, Zheng M, Chen MM, Tian LX., Free PMC Article | 11/6/2021 |
| Silencing of AHNAK2 restricts thyroid carcinoma progression by inhibiting the Wnt/beta-catenin pathway. | Silencing of AHNAK2 restricts thyroid carcinoma progression by inhibiting the Wnt/β-catenin pathway.
Lin QY, Qi QL, Hou S, Chen Z, Jiang N, Zhang L, Lin CH. | 10/16/2021 |
| AHNAK2 is a novel prognostic marker and correlates with immune infiltration in papillary thyroid cancer: Evidence from integrated analysis. | AHNAK2 is a novel prognostic marker and correlates with immune infiltration in papillary thyroid cancer: Evidence from integrated analysis.
Zheng L, Li S, Zheng X, Guo R, Qu W. | 05/29/2021 |
| Correlation between prognostic indicator AHNAK2 and immune infiltrates in lung adenocarcinoma. | Correlation between prognostic indicator AHNAK2 and immune infiltrates in lung adenocarcinoma.
Zheng M, Liu J, Bian T, Liu L, Sun H, Zhou H, Zhao C, Yang Z, Shi J, Liu Y. | 05/29/2021 |
| AHNAK2 Is Associated with Poor Prognosis and Cell Migration in Lung Adenocarcinoma. | AHNAK2 Is Associated with Poor Prognosis and Cell Migration in Lung Adenocarcinoma.
Zhang S, Lu Y, Qi L, Wang H, Wang Z, Cai Z., Free PMC Article | 05/8/2021 |
| Linkage analysis and whole exome sequencing reveals AHNAK2 as a novel genetic cause for autosomal recessive CMT in a Malaysian family. | Linkage analysis and whole exome sequencing reveals AHNAK2 as a novel genetic cause for autosomal recessive CMT in a Malaysian family.
Tey S, Shahrizaila N, Drew AP, Samulong S, Goh KJ, Battaloglu E, Atkinson D, Parman Y, Jordanova A, Chung KW, Choi BO, Li YC, Auer-Grumbach M, Nicholson GA, Kennerson ML, Ahmad-Annuar A. | 08/29/2020 |
| Results illustrated that AHNAK2 was upregulated in UM and plays a promoting role in the proliferation and migration of UM cells possibly via regulating PI3K signaling pathway. | AHNAK Nucleoprotein 2 Performs a Promoting Role in the Proliferation and Migration of Uveal Melanoma Cells.
Li M, Liu Y, Meng Y, Zhu Y. | 04/11/2020 |
| AHNAK2 is overexpressed in PDAC tissues and is an independent prognostic factor in patients with PDAC. | AHNAK2 is a potential prognostic biomarker in patients with PDAC.
Lu D, Wang J, Shi X, Yue B, Hao J., Free PMC Article | 03/31/2018 |
| The authors reveal that AHNAK2 is upregulated in clear cell renal cell carcinoma cells and hypoxic upregulation of AHNAK2 can drive tumorigenesis and progression by supporting EMT and cancer cell stemness. | AHNAK2 is a Novel Prognostic Marker and Oncogenic Protein for Clear Cell Renal Cell Carcinoma.
Wang M, Li X, Zhang J, Yang Q, Chen W, Jin W, Huang YR, Yang R, Gao WQ., Free PMC Article | 01/6/2018 |
| Periaxin and AHNAK nucleoprotein 2 form intertwined homodimers through domain swapping | Periaxin and AHNAK nucleoprotein 2 form intertwined homodimers through domain swapping.
Han H, Kursula P., Free PMC Article | 12/20/2014 |